WuXi Biologics

Shanghai, China Founded: 2008 • Age: 18 yrs
Protein therapeutics are developed and manufactured by WuXi Biologics.
Request Access

About WuXi Biologics

WuXi Biologics is a company based in Shanghai (China) founded in 2008.. The company has 12,570 employees as of December 31, 2024. WuXi Biologics has completed 1 acquisition, including CMAB Biopharma. WuXi Biologics operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.

  • Headquarter Shanghai, China
  • Employees 12570 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Wuxi Biologics (Cayman) Inc.
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
    $2.61 B (USD)
    7.57
    as on Dec 31, 2024
  • Net Profit
    $468.68 M (USD)
    -3.14
    as on Dec 31, 2024
  • EBITDA
    $871.69 M (USD)
    15.21
    as on Dec 31, 2024
  • Latest Funding Round
  • Investors
  • Employee Count
    12570

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of WuXi Biologics

WuXi Biologics is a publicly listed company on the HKEX with ticker symbol 2269 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: HKEX · Ticker: 2269 . Sector: Health technology · Hong Kong
People of WuXi Biologics
Headcount 10000+
Employee Profiles 248
Employee Profiles
People
Zhisheng Chen
CEO
People
Brian Sommers
SR Facilities Manager
People
Gary Hamilton
Associate Director Process Engineering And Validation
People
JiJie Gu
Chief Scientific Officer & EVP

Unlock access to complete

Funding Insights of WuXi Biologics

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by WuXi Biologics

WuXi Biologics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CMAB Biopharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Biologic products are developed and manufactured for clinical stages.
2017
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - WuXi Biologics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Wuxi Biologics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of WuXi Biologics

WuXi Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
R&D focused on manufacturing of drugs for multiple therapeutic areas
domain founded_year HQ Location
CDMO offering drug and biologics development services
domain founded_year HQ Location
Selective Wnt agonists are developed for human tissue regeneration.
domain founded_year HQ Location
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
domain founded_year HQ Location
Drug research, development, testing, and consulting services are provided.
domain founded_year HQ Location
Provides contract research, development, and manufacturing services for biologic drugs.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about WuXi Biologics

When was WuXi Biologics founded?

WuXi Biologics was founded in 2008.

Where is WuXi Biologics located?

WuXi Biologics is headquartered in Shanghai, China.

How many employees does WuXi Biologics have?

As of Dec 31, 2024, the latest employee count at WuXi Biologics is 12,570.

What is the annual revenue of WuXi Biologics?

Annual revenue of WuXi Biologics is $2.61B as on Dec 31, 2024.

What does WuXi Biologics do?

WuXi Biologics was founded in 2008 and is headquartered in Shanghai, China. Operations focus on the biologics sector, where protein therapeutics are developed and manufactured for global clients. Services include end-to-end solutions from research to production. In 2022, annual revenues of 2.27 billion were recorded, alongside a net profit of 0.66 billion. The domain wuxibiologics.com supports its online presence.

Who are the top competitors of WuXi Biologics?

WuXi Biologics's top competitors include Novartis, Surrozen and Catalent.

Is WuXi Biologics publicly traded?

Yes, WuXi Biologics is publicly traded on HKEX under the ticker symbol 2269.

How many acquisitions has WuXi Biologics made?

WuXi Biologics has made 1 acquisition, including CMAB Biopharma.

What is WuXi Biologics's ticker symbol?

The ticker symbol of WuXi Biologics is 2269 on HKEX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available